Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy
Open accessThe DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index; 21 of the 126 sources its claims cite were checked for support.
Abstract
Inherited retinal diseases (IRDs) are a leading cause of blindness in industrialized countries, and gene therapy is quickly becoming a viable option to treat this group of diseases. Gene replacement using a viral vector has been successfully applied and advanced to commercial use for a rare group of diseases. This, and the advances in gene editing, are paving the way for the emergence of a new generation of therapies that use CRISPR–Cas9 to edit mutated genes in situ. These CRISPR-based agents can be delivered to the retina as transgenes in a viral vector, unpackaged transgenes or as proteins or messenger RNA using non-viral vectors. Although the eye is considered to be an immune-privileged organ, studies in animals, as well as evidence from clinics, have concluded that ocular gene therapies elicit an immune response that can under certain circumstances result in inflammation. In this review, we evaluate studies that have reported on pre-existing immunity, and discuss both innate and adaptive immune responses with a specific focus on immune responses to gene editing, both with non-viral and viral delivery in the ocular space. Lastly, we discuss approaches to prevent and manage the immune responses to ensure safe and efficient gene editing in the retina.
Overview
CoChat Summary
TL;DR
This narrative review examines pre-existing and post-treatment innate and adaptive immune responses to retinal gene therapy, covering viral vectors (AAV, lentivirus, adenovirus), non-viral delivery (naked DNA, lipoplexes, polymers, nanoparticles, VLPs), and CRISPR-Cas9 components. It argues that the eye's immune privilege is not absolute and surveys vector-oriented and immune-response-oriented strategies to prevent or manage these responses.
Key findings
- Pre-existing immunity to Cas9 is common: in 125 healthy US adult blood donors (median age 43), anti-SaCas9 and anti-SpCas9 antibodies were found in 78% and 58% respectively; 78% had SaCas9-specific T-cells and 67% SpCas9-specific T-cells. A canine study found anti-SpCas9 antibodies in all 78 adult animals but not in 16 newborns.
- Pre-existing anti-AAV seroprevalence is high and serotype-dependent: in 226 healthy donors, serum IgG prevalence was AAV2 72%, AAV1 67%, AAV9 47%, AAV6 46%, AAV5 40%, AAV8 38%; in 888 serum samples across 10 countries, AAV2 was highest and the novel variant AAVrh32.33 lowest.
- Clinical ocular gene therapy trials report inflammation: in NCT00999609 (Phase 3), mild inflammation in 2 of 21 patients; in NCT02781480 (Phase 1/2), uveitis in 1/3 low-dose, 3/3 intermediate-dose and 2/3 high-dose patients; in an AMD Ad trial, 25% of 28 patients developed transient intraocular inflammation; in a retinoblastoma cohort, 5 of 8 patients developed ocular inflammation without measurable humoral or cellular response.
- Non-viral vectors are not necessarily less immunogenic: chitosan induced inflammatory cell infiltration and retinal degeneration in rabbits, while gold nanoparticles reduced LPS-induced inflammation via the TLR4-NFκB pathway; VLP-mediated base editing reached >95% efficiency in fibroblasts, 53–55% in mouse CNS, 63% in liver, and 21% in RPE with visual rescue in rd12 mice.
Methods
- Narrative review; no experimental data were generated or presented (stated explicitly in the Institutional Review Board, Data Availability, and Additional Information statements).
- Synthesizes published human, non-human primate, canine, rodent and in vitro studies on pre-existing immunity, innate and adaptive responses to viral and non-viral ocular delivery, and immunosuppressive strategies.
- No systematic search protocol, inclusion criteria, or quantitative synthesis is described.
Limitations
- Stated by the paper: immune responses are "highly individualistic," making concrete conclusions from small patient cohorts difficult; mechanistic insights into how responses occur at cellular or molecular levels are missing; immunosuppressive regimens are rarely reported in animal studies and inadequately documented in human studies, and no systematic comparative studies of corticosteroids exist.
- Evident from the text: as a narrative review without a described search strategy, selection of cited studies may be non-exhaustive; several cited findings rest on very small samples (e.g., 3 serum samples, 3 patients, 8 patients), and the review itself notes that long-term immune-response data after Cas9 delivery in patients are not yet available.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
16 Valid · 6 Not valid · 96 Not checked · 40 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, a study conducted on 41 non-human primates (NHP) revealed that the highest level of antibodies was against AAV8 and AAV9 [30].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 2. Pre-Existing Immunity
What the sources say
- Supportedcites [30] Ail, 2022, Systemic and Local Immune Responses to Intraocular AAV Vector Administration in Non-Human Primates, Mol. Ther.-Methods Clin. Dev. source
The Results section (‘Seroprevalence of antibodies against frequently used AAV serotypes in NHP population’) reports testing 41 NHPs and finding the highest antibody levels against AAV8, followed by AAV9, among the four serotypes tested. The claim accurately identifies the two highest, though AAV8 levels were higher than AAV9 levels. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This study also showed that the antibodies' levels were higher in serum than in vitreous liquid [26].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 2. Pre-Existing Immunity
What the sources say
- Supportedcites [26] Toral, 2022, Investigation of Cas9 Antibodies in the Human Eye, Nat. Commun. source
The Results section (‘Characterization of human vitreous fluid antibodies’) reports an aggregate vitreous-to-serum antibody concentration ratio of approximately 1:143, with sample-to-sample differences. That directly supports the claim that antibody levels were higher in serum than in vitreous fluid. (LLM, conf=0.94)
plainn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In humans as well as NHPs, the pre-existing antibodies against AAV5 tend to be lower [28,30].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 2. Pre-Existing Immunity
What the sources say
- Not checked yetcites [28] Boutin, 2010, Prevalence of Serum IgG and Neutralizing Factors against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors, Hum. Gene Ther. source
- Supportedcites [30] Ail, 2022, Systemic and Local Immune Responses to Intraocular AAV Vector Administration in Non-Human Primates, Mol. Ther.-Methods Clin. Dev. source
The Discussion states that anti-AAV5 antibody levels were low in all NHP samples tested, as they are in human samples. The Results also report lower anti-AAV5 levels than anti-AAV8 and anti-AAV9 levels in the tested NHPs. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results showed that there was a higher expression of innate responserelated genes and IFN-β secretion in groups that received 5 -ppp gRNAs.”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 3. Immune Response to Cas Proteins
What the sources say
- Supportedcites [38] Kim, 2018, CRISPR RNAs Trigger Innate Immune Responses in Human Cells, Genome Res. source
In the Results section on primary human T cells, 5′-ppp sgRNA up-regulated OAS2 and DDX58 mRNA in CD4+ T cells, and IFNB1 protein was detected in the supernatant. The same passage says 5′-OH sgRNA induced no detectable immune response compared with the mock control; the Methods identify the IFNB1 assay as measuring protein secreted into the medium. Page numbers are not available in the supplied copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“They showed that in primary human and mouse fibroblasts, VLP-mediated base editing could be achieved with more than 95% efficiency.”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 6. Immune Response to Non-Viral Vectors
What the sources say
- Supportedcites [83] Banskota, 2022, Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins, Cell source
The Results section 'v4 BE-eVLPs efficiently edit primary human and mouse cells' states that after transducing primary human patient-derived fibroblasts homozygous for COL7A1(R185X) with v4 BE-eVLPs, >95% editing was observed at the target adenine, and that >95% correction of the Idua(W392X) mutation was seen in primary mouse fibroblasts (Figure 4A/4B). The same passage concludes that v4 BE-eVLPs can achieve base editing levels in primary human and mouse fibroblasts approaching 100%, matching the paraphrase. (LLM, conf=0.93)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
73 more claims · 8 with their cited sources checked
Create a free account to see all 158 claims and to verify the 105 references still open.
- It may state two separate claims as one. 72
- Probably not a substantial claim. 11
- The quote only partly states this claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immunogenicity against the viral vector that limits gene therapy efficacy is a major concern.4,21,25,26,141 and is one of the biggest exclusion criteria in clinical trials.14,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several studies have observed antidrug antibody responses and inflammation in the eyes due to immune cell infiltration following retinal gene therapy.21,23–27”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [25]
In the citing paper
“In addition to neutralizing antibodies, cell based immune responses have often been observed at higher doses (above 1 × 1011 vg) in many ocular gene therapy trials.25,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 1. Introduction
“Adenoviruses (Ads), which can reach a packaging capacity of 37 kb [12].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 5. Immune Response to Other Viral Vectors
“Adenoviruses (Ads) can offer one of the largest capacities for delivering transgenes of up to 36 kb [12].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 3. Immune Response to Cas Proteins
“a CRISPR-Cas9-based gene therapy to correct this mutation called EDIT-101 was evaluated in a pre-clinical study.”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 3. Immune Response to Cas Proteins
“The promising results of this pre-clinical study gave rise to a gene-editing product named EDIT-10”
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947 · cited 1×
“CRISPR-associated proteins (Cas) are present in most archaea and bacteria as adaptive immune systems [31] and provide sequence-specific resistance against phages [32].”
BackgroundHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
An updated evolutionary classification of CRISPR–Cas systems
Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., Saunders, S. J., Barrangou, R., Brouns, S. J. J., Charpentier, E., Haft, D. H., et al. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3569 · Cited by 2,480 · cited 1×
“CRISPR-associated proteins (Cas) are present in most archaea and bacteria as adaptive immune systems [31] and provide sequence-specific resistance against phages [32].”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“In a LCA clinical trial (NCT00999609, Phase 3), mild inflammation was observed in 2 of the 21 patients who received the RPE65 gene packaged in AAV2 vectors [45].”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“AAV is the most widely used vector for ocular gene therapy due to its non-pathogenic nature [42], transduction efficiency and ability to transduce a wide variety of cell types [43].”
BackgroundIdentification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Clinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930 · cited 1×
“Additionally, they are genome-integrating, and their integration can at times occur at an oncogenic locus [13].”
BackgroundDisease Manifestations and Pathogenic Mechanisms of Group A Streptococcus
Walker, M. J., Barnett, T. C., McArthur, J. D., Cole, J. N., Gillen, C. M., Henningham, A., Sriprakash, K. S., Sanderson-Smith, M. L., & Nizet, V. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00101-13 · Cited by 908 · cited 1×
“The most widely used Cas9 orthologs are derived from Staphylococcus aureus (SaCas9) and Streptococcus pyogenes (SpCas9) [4], which are common human commensals that could sometimes become pathogenic [22,23].”
BackgroundNooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869 · cited 1×
“One of the most exploited applications of VLPs is in vaccine development, wherein they are modified to present epitopes that elicit specific T-cell and humoral responses [82].”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743 · cited 1×
“The results showed that retinal sensitivity was improved; however, the final transgene expression in the participants from the high dose group was adversely affected by ocular inflammation or immune responses [48].”
BackgroundCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743 · cited 1×
“AAVs provide long-term transgene expression, induce a low host immune response, infect both dividing and quiescent cells and do not integrate into the host genome, thereby reducing the risk to patients [9].”
BackgroundParks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725 · cited 3×
“Adenoviruses (Ads) can offer one of the largest capacities for delivering transgenes of up to 36 kb [12].”
BackgroundMethodDevelopment of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Nonviral Gene Delivery: Principle, Limitations, and Recent Progress
Al-Dosari, M. S., & Gao, X. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9143-y · Cited by 706 · cited 2×
“However, so far, non-viral vectors have proven to be less efficient than viral vectors [67].”
BackgroundNatural Polymers for Gene Delivery and Tissue Engineering
DANG, J., & LEONG, K. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.001 · Cited by 694 · cited 1×
“However, so far most of these strategies have reported low efficiency and could not accomplish transgene expression at therapeutic levels [18].”
BackgroundEngineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins
Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.021 · Cited by 668 · cited 1×
“Although analyses of immune responses were not performed, they reported low toxicity based on the data from liver delivery [83].”
BackgroundA Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617 · cited 2×
“Interestingly, both AAV9 and Cas9 induced the production of specific antibodies, while only Cas9 induced the cellular immune response [40].”
BackgroundAdenovirus vectors for gene therapy, vaccination and cancer gene therapy
Wold, W., & Toth, K. (2014) · Current Gene Therapy · doi:10.2174/1566523213666131125095046 · Cited by 555
Simonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553 · cited 1×
“Transient and low levels of anti-AAV2 neutralizing antibodies (NAbs) were detected in two out of three patients, one at day 14 and the other at day 90, which decreased to baseline 1-year post-injection [46].”
BackgroundDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 1×
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
BackgroundStable and efficient gene transfer into the retina using an HIV-based lentiviral vector
Miyoshi, H., Takahashi, M., Gage, F. H., & Verma, I. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10319 · Cited by 494 · cited 1×
“Several macrophages were observed surrounding the injection site, which the authors ascribed to surgical damage as a similar phenomenon was observed in the control animals [56].”
BackgroundLatest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
Naeem, M., Majeed, S., Hoque, M. Z., & Ahmad, I. (2020) · Cells · doi:10.3390/cells9071608 · Cited by 457
Segel, M., Lash, B., Song, J., Ladha, A., Liu, C. C., Jin, X., Mekhedov, S. L., Macrae, R. K., Koonin, E. V., & Zhang, F. (2021) · Science · doi:10.1126/science.abg6155 · Cited by 423 · cited 1×
“Immune responses have not been evaluated, but SEND may have reduced immunogenicity compared to currently available viral vectors due to its use of endogenous human proteins [85].”
BackgroundHigh prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Wagner, D. L., Amini, L., Wendering, D. J., Burkhardt, L.-M., Akyüz, L., Reinke, P., Volk, H.-D., & Schmueck-Henneresse, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0204-6 · Cited by 399 · cited 1×
“Another study conducted on 48 healthy donors also confirmed this finding of a high prevalence of T-cells against SpCas9 protein, demonstrating that SpCas9 stimulation could activate CD137+ and CD154+ T-cells [25].”
ResultViral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391 · cited 1×
“VLPs can be used as carriers to deliver small molecules, genes and nucleic acids, or peptides and proteins in cancer therapies, immunotherapies, vaccines and gene therapies [81].”
BackgroundCurrent Progress in Gene Delivery Technology Based on Chemical Methods and Nano-Carriers
Jin, L., Zeng, X., Liu, M., Deng, Y., & He, N. (2014) · Theranostics · doi:10.7150/thno.6914 · Cited by 388 · cited 1×
“Although these polyplexes do not contain any viral material, they are still foreign materials and they may lead to the immune response by the host [74].”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355 · cited 1×
“When AAV8-hFIX with mutated AAV8 decoys were injected in WT C57BL/6 mice immunized with intravenous immunoglobulin (IVIg), the transgene expression increased with the amount of AAV empty capsid [91].”
Mangeot, P. E., Risson, V., Fusil, F., Marnef, A., Laurent, E., Blin, J., Mournetas, V., Massouridès, E., Sohier, T. J. M., Corbin, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07845-z · Cited by 346 · cited 1×
“In the mouse liver, they were able to show 7–13% editing efficiency [84].”
BackgroundAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“AAV is the most widely used vector for ocular gene therapy due to its non-pathogenic nature [42], transduction efficiency and ability to transduce a wide variety of cell types [43].”
BackgroundWang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345 · cited 1×
“The transgene-GFP expression was observed on day 3, started decreasing from day 7 and finally disappeared at day 14 [39].”
BackgroundCampochiaro, P. A., Nguyen, Q. D., Shah, S. M., Klein, M. L., Holz, E., Frank, R. N., Saperstein, D. A., Gupta, A., Stout, J. T., Macko, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.167 · Cited by 343
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336
CRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 328 · cited 6×
“To explore this potential risk, guide RNAs with a 5′-triphosphate group (5′-ppp gRNAs) or gRNAs with 5′-hydroxyl were delivered to primary human CD4+ T cells with or without recombinant Cas9 as a ribonucleoprotein (RNP) complex.”
BackgroundInfluentialLynch, J., Fishbein, M., & Echavarria, M. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1283287 · Cited by 301
Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk
Vollrath, D., Feng, W., Duncan, J. L., Yasumura, D., D'Cruz, P. M., Chappelow, A., Matthes, M. T., Kay, M. A., & LaVail, M. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221364198 · Cited by 290 · cited 1×
“Delivery of Ad encoding the Mertk gene to the RPE of RCS rats (a retinal degeneration model), rescued RPE dysfunction [61].”
BackgroundLi, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261 · cited 1×
“A novel variant selected from this screen—chimeric-1829—showed higher transduction efficiency and low cross-reactivity with the pre-existing antibodies against other serotypes, indicating that the immune response may not recognize chimeric-1829 [90].”
BackgroundCpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · cited 3×
“In Tlr9-deficient mice, IFN-γ T cell responses toward capsid and transgene were suppressed, resulting in a minimal cellular infiltrate and stable transgene expression [94].”
BackgroundInfluentialFunctional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252 · cited 1×
“Additionally, there was a two-fold increase in anti-AAV antibodies in dogs that received AAV [50].”
BackgroundMolecular Anatomy of the Developing Human Retina
Hoshino, A., Ratnapriya, R., Brooks, M. J., Chaitankar, V., Wilken, M. S., Zhang, C., Starostik, M. R., Gieser, L., La Torre, A., Nishio, M., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.10.029 · Cited by 251 · cited 1×
“IRDs can result in severe visual impairment or complete vision loss, and are a social and economic burden [1].”
BackgroundDosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242 · cited 2×
“An increase in dose implies an increase in vector, transgene and promoter—each of which has independently and cumulatively shown to affect immune responses [30,52,86,87].”
BackgroundBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242 · cited 1×
“Innate immune responses can further boost adaptive immune responses to generate antibodies or cytotoxic T cells, which limit the transduction efficiency of the vector and/or clear the transduced cells (Figure 1) [21].”
BackgroundCRISPR RNAs Trigger Innate Immune Responses in Human Cells
Kim, S., Koo, T., Jee, H.-G., Cho, H.-Y., Lee, G., Lim, D.-G., Shin, H. S., & Kim, J.-S. (2018) · Genome Research · doi:10.1101/gr.231936.117 · Cited by 222 · cited 1×
“Thus, immune responses against the guide RNAs should also be considered to have a complete overview of the potential immune responses against the CRISPR/Cas9 system [38].”
BackgroundWeleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., Jensen, L., McBride, M. T., Flotte, T. R., Humphries, M., Calcedo, R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.003 · Cited by 218 · cited 2×
“In NCT00749957 (Phase 1/2), three out of six patients who received a high dose of AAV showed ocular inflammation, even though the T-cell responses to capsid and the transgene product were not observed by ELISpot [47].”
BackgroundTse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210 · cited 1×
“Variants developed based on this analysis required 2- to 16-fold higher antibodies for neutralization compared to their parental serotype [89].”
BackgroundMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
A Thermostable Cas9 with Increased Lifetime in Human Plasma
Harrington, L. B., Paez-Espino, D., Staahl, B. T., Chen, J. S., Ma, E., Kyrpides, N. C., & Doudna, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01408-4 · Cited by 205 · cited 2×
“In GFP-expressing HEK293T cells, GeoCas9 showed editing efficiency comparable to SpCas9 when used for the disruption of GFP function [97].”
BackgroundMethodMultifunctional CRISPR-Cas9 with Engineered Immunosilenced Human T Cell Epitopes
Ferdosi, S. R., Ewaisha, R., Moghadam, F., Krishna, S., Park, J. G., Ebrahimkhani, M. R., Kiani, S., & Anderson, K. S. (2019) · Nature Communications · doi:10.1038/s41467-019-09693-x · Cited by 204 · cited 1×
“This finding demonstrated that Cas9 proteins can be modified to eliminate immunodominant epitopes through targeted mutations while preserving its function and specificity (Figure 2) [96].”
BackgroundBainbridge, J., Stephens, C., Parsley, K., Demaison, C., Halfyard, A., Thrasher, A., & Ali, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301574 · Cited by 197 · cited 1×
“In another study, HIV vectors carrying GFP were delivered by subretinal injection—a stable expression was observed in RPE, and no inflammatory cell infiltration was observed by immunostaining [57].”
BackgroundEarly and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
Self-citationVector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183 · cited 2×
“These form a complex with DNA, drugs or proteins, and are transferred into cells [7].”
BackgroundImmunogenicity of Cas9 Protein
Mehta, A., & Merkel, O. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.003 · Cited by 183 · cited 8×
“To explore this potential risk, guide RNAs with a 5′-triphosphate group (5′-ppp gRNAs) or gRNAs with 5′-hydroxyl were delivered to primary human CD4+ T cells with or without recombinant Cas9 as a ribonucleoprotein (RNP) complex.”
BackgroundInfluentialAdeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178 · cited 1×
“Furthermore, recombinant AAV (rAAV) rarely integrates into the host cell genome, thereby reducing the risk of insertional mutagenesis following gene therapy [44].”
BackgroundA catalogue of biochemically diverse CRISPR-Cas9 orthologs
Gasiunas, G., Young, J. K., Karvelis, T., Kazlauskas, D., Urbaitis, T., Jasnauskaite, M., Grusyte, M. M., Paulraj, S., Wang, P.-H., Hou, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19344-1 · Cited by 177
Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26830-7 · Cited by 175
Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147 · cited 1×
“An increase in dose implies an increase in vector, transgene and promoter—each of which has independently and cumulatively shown to affect immune responses [30,52,86,87].”
BackgroundChévez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M. Y., & Hurwitz, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.1883 · Cited by 143 · cited 2×
“Two clinical trials have been conducted to test treatments for AMD [64] and retinoblastoma [65].”
BackgroundGenome Editing Abrogates Angiogenesis in Vivo
Huang, X., Zhou, G., Wu, W., Duan, Y., Ma, G., Song, J., Xiao, R., Vandenberghe, L., Zhang, F., D’Amore, P. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00140-3 · Cited by 142 · cited 1×
“They analyzed toxicity and inflammation by imaging the fundus as well as immunolabeling the retina for inflammation markers but reported no damage to the retina four weeks post-injection [36].”
BackgroundZou, M., Ke, Q., Nie, Q., Qi, R., Zhu, X., Liu, W., Hu, X., Sun, Q., Fu, J.-L., Tang, X., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00967-4 · Cited by 138 · cited 1×
“The study demonstrated that cGAS-STING would be activated when cytosolic DNA is found in the retina, resulting in DNA clearance and local inflammation, which is likely to be a barrier for naked DNA delivery [71].”
BackgroundMoreno, A. M., Palmer, N. D., Alemán, F., Chen, G., Pla, A., Jiang, N. J., Chew, W. L., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 134
Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing
Han, H. A., Pang, J. K. S., & Soh, B.-S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01893-z · Cited by 134
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117 · cited 1×
“This leads to innate immune responses eventually recruiting other immune cells to the site of infection and further triggers adaptive immune responses (Figure 2) [99].”
BackgroundOcular Nanoparticle Toxicity and Transfection of the Retina and Retinal Pigment Epithelium
Prow, T. W., Bhutto, I., Kim, S. Y., Grebe, R., Merges, C., McLeod, D. S., Uno, K., Mennon, M., Rodriguez, L., Leong, K., et al. (2008) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.06.003 · Cited by 111 · cited 1×
“These results further reiterate that non-viral vectors not only lack efficiency for ocular delivery applications but can also induce immune responses [75].”
BackgroundImmune Responses Limit Adenovirally Mediated Gene Expression in the Adult Mouse Eye
Reichel, M., Ali, R., Thrasher, A., Hunt, D., Bhattacharya, S., & Baker, D. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300691 · Cited by 106 · cited 1×
“The data demonstrated that the transgene expression decreased with time due to the immune response elicited by Ad, whereas when T-cells were deleted transiently, the expression could stay longer but would be eliminated once the transient depletion reagent delivery was stopped [63].”
BackgroundCapsid-specific removal of circulating antibodies to adeno-associated virus vectors
Bertin, B., Veron, P., Leborgne, C., Deschamps, J.-Y., Moullec, S., Fromes, Y., Collaud, F., Boutin, S., Latournerie, V., van Wittenberghe, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57893-z · Cited by 100
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 97 · cited 2×
“Many engineered viral vectors have been successfully used for gene therapy applications [8].”
BackgroundRapid ocular angiogenic control via naked DNA delivery to cornea.
Stechschulte, S. U., Joussen, A. M., von Recum, H. A., Poulaki, V., Moromizato, Y., Yuan, J., D’Amato, R. J., Kuo, C. J., & Adamis, A. P. (2001) · PubMed · Cited by 96
Gene therapy for inherited retinal diseases
Nuzbrokh, Y., Ragi, S. D., & Tsang, S. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4726 · Cited by 94
Lipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93 · cited 1×
“Even though one of the early motivations for developing non-viral vectors was to avoid viral components to have lower immunogenicity [78,79], these studies highlight that depending on the non-viral vectors used, the immune consequence could be severe, as is in the case of chitosan, or could be protective, as shown by…”
BackgroundZhao, H., Hemmi, H., Akira, S., Cheng, S. H., Scheule, R. K., & Yew, N. S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.012 · Cited by 85 · cited 2×
“The depletion of CpG sequences in the viral genome helped reduce immune responses (Figure 2) [72,95].”
BackgroundRPE65 Gene Delivery Restores Isomerohydrolase Activity and Prevents Early Cone Loss in Rpe65−/−Mice
Chen, Y., Moiseyev, G., Takahashi, Y., & Ma, J.-X. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0965 · Cited by 80 · cited 1×
“To restore the early cone loss in Rpe65-/- mice, Ad expressing RPE65 was delivered to Rpe65-/- mice and high levels of RPE65 expression were reported [60].”
BackgroundNon-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80 · cited 3×
“The intention of developing such techniques is to have larger packaging capacities or to deliver genes without packaging to avoid viral components—and hence, be less immunogenic—and for the ease of large-scale productions [17].”
BackgroundDuisit, G., Conrath, H., Saleun, S., Folliot, S., Provost, N., Cosset, F.-L., Sandrin, V., Moullier, P., & Rolling, F. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0690 · Cited by 79
Effects of Gold Nanoparticles on Endotoxin-Induced Uveitis in Rats
Pereira, D. V., Petronilho, F., Pereira, H. R. S. B., Vuolo, F., Mina, F., Possato, J. C., Vitto, M. F., de Souza, D. R., da Silva, L., da Silva Paula, M. M., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10743 · Cited by 76 · cited 1×
“These findings interestingly suggest that topical GNP decreases intraocular inflammation and oxidative damage by interfering with the TLR4–NFκB pathway [77].”
BackgroundOrlowski, A., Katz, M. G., Gubara, S. M., Fargnoli, A. S., Fish, K. M., & Weber, T. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.004 · Cited by 74
Lentiviral vectors for treating and modeling human CNS disorders
Azzouz, M., Kingsman, S. M., & Mazarakis, N. D. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.600 · Cited by 73 · cited 1×
“The three main LV vectors used for gene therapy are human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV) and equine infectious anemia virus (EIAV), which is of non-primate origin [55].”
MethodOcular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in the Mouse Retina
Ding, X.-Q., Quiambao, A. B., Fitzgerald, J. B., Cooper, M. J., Conley, S. M., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007410 · Cited by 71 · cited 1×
“Even though one of the early motivations for developing non-viral vectors was to avoid viral components to have lower immunogenicity [78,79], these studies highlight that depending on the non-viral vectors used, the immune consequence could be severe, as is in the case of chitosan, or could be protective, as shown by…”
BackgroundGene therapy in inherited retinal degenerative diseases, a review
Takahashi, V. K. L., Takiuti, J. T., Jauregui, R., & Tsang, S. H. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1495745 · Cited by 66
Ye, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64 · cited 1×
“Furthermore, intraocular inflammation was observed one-week post-injection and recovered with time [51].”
BackgroundInsights into the Geobacillus stearothermophilus species based on phylogenomic principles
Burgess, S. A., Flint, S. H., Lindsay, D., Cox, M. P., & Biggs, P. J. (2017) · BMC Microbiology · doi:10.1186/s12866-017-1047-x · Cited by 62 · cited 1×
“As Geobacillus stearothermophilus thrive in harsh environments such as hot spring cool soils [98], humans may not have as a high prevalence of antibodies against GeoCas9 as SpCas9.”
BackgroundA pursuit of Staphylococcus aureus continues: a role of persister cells
Chang, J., Lee, R.-E., & Lee, W. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01246-x · Cited by 62 · cited 1×
“The most widely used Cas9 orthologs are derived from Staphylococcus aureus (SaCas9) and Streptococcus pyogenes (SpCas9) [4], which are common human commensals that could sometimes become pathogenic [22,23].”
BackgroundSystemic and local immune responses to intraocular AAV vector administration in non-human primates
Ail, D., Ren, D., Brazhnikova, E., Nouvel-Jaillard, C., Bertin, S., Mirashrafi, S. B., Fisson, S., & Dalkara, D. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.011 · Cited by 61 · cited 6×
“Interestingly, both AAV9 and Cas9 induced the production of specific antibodies, while only Cas9 induced the cellular immune response [40].”
BackgroundInfluentialSelf-citationRetinal transduction profiles by high-capacity viral vectors
Puppo, A., Cesi, G., Marrocco, E., Piccolo, P., Jacca, S., Shayakhmetov, D. M., Parks, R. J., Davidson, B. L., Colloca, S., Brunetti‐Pierri, N., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.57 · Cited by 61
Controlled Gene Gun Delivery and Expression of DNA Within the Cornea
Tanelian, D. L., Barry, M. A., Johnston, S. A., Le, T. T., & Smith, G. M. (1997) · BioTechniques · doi:10.2144/97233st06 · Cited by 59 · cited 1×
“The study reported a GFP expression without the presence of inflammatory cells in the cornea [68].”
BackgroundBai, B., Hu, Q., Hu, H., Zhou, P., Shi, Z., Meng, J., Lu, B., Huang, Y., Mao, P., & Wang, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002685 · Cited by 59 · cited 1×
“VLPs are nanoscale structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle, but lacking the viral genetic material and being non-infectious [80].”
BackgroundLamartina, S., Cimino, M., Roscilli, G., Dammassa, E., Lazzaro, D., Rota, R., Ciliberto, G., & Toniatti, C. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1083 · Cited by 59 · cited 1×
“HdAd promoted a long-lasting (up to one year) transgene expression in the retina, whereas the FGAd-mediated expression decreased after two months due to immune response-related clearance [92].”
BackgroundSalas, D., Kwikkers, K. L., Zabaleta, N., Bazo, A., Petry, H., van Deventer, S. J., Aseguinolaza, G. G., & Ferreira, V. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000380 · Cited by 59
Stable RAAV-Mediated Transduction of Rod and Cone Photoreceptors in the Canine Retina
Bainbridge, J. W. B., Mistry, A., Schlichtenbrede, F. C., Smith, A., Broderick, C., De Alwis, M., Georgiadis, A., Taylor, P. M., Squires, M., Sethi, C., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301990 · Cited by 58 · cited 1×
“However, evidence of an intraocular inflammatory response was reported in three out of eight animals [49].”
BackgroundTLR9 Ligand CpG-ODN Applied to the Injured Mouse Cornea Elicits Retinal Inflammation
Chinnery, H. R., McLenachan, S., Binz, N., Sun, Y., Forrester, J. V., Degli-Esposti, M. A., Pearlman, E., & McMenamin, P. G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.09.041 · Cited by 46 · cited 2×
“The depletion of CpG sequences in the viral genome helped reduce immune responses (Figure 2) [72,95].”
BackgroundMethodIn Vivo Gene Delivery in the Retina Using Polyethylenimine
Liao, H.-W., & Yau, K.-W. (2007) · BioTechniques · doi:10.2144/000112404 · Cited by 46 · cited 1×
“The DsRed expression was observed in GCL, while the melanopsin expression decreased, providing evidence for the suitability of polyplexes for ocular gene delivery [73].”
BackgroundCD4+ CD25+ regulatory T cells inhibit immune-mediated transgene rejection
Gross, D.-A., Leboeuf, M., Gjata, B., Danos, O., & Davoust, J. (2003) · Blood · doi:10.1182/blood-2003-05-1454 · Cited by 45
Polymeric Vectors for Ocular Gene Delivery
Tamboli, V., Mishra, G. P., & Mitra, A. K. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.20 · Cited by 45 · cited 1×
“These methods can include the direct delivery of proteins or DNA by physical or chemical methods, such as conjugation with liposomes, polymers and nanoparticles (Figure 1) [66].”
MethodVendomèle, J., Khebizi, Q., & Fisson, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01686 · Cited by 44
Self-citationKalesnykas, G., Kokki, E., Alasaarela, L., Lesch, H. P., Tuulos, T., Kinnunen, K., Uusitalo, H., Airenne, K., & Yla-Herttuala, S. (2017) · Current Gene Therapy · doi:10.2174/1566523217666171003170348 · Cited by 43 · cited 1×
“performed by ELISA on serum samples revealed that Ad induced the highest levels of antibody production, followed by LV, BV and AAV [54].”
MethodSakurai, H., Sakurai, F., Kawabata, K., Sasaki, T., Koizumi, N., Huang, H., Tashiro, K., Kurachi, S., Nakagawa, S., & Mizuguchi, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.11.030 · Cited by 40 · cited 1×
“Additionally, as elaborated in the following sections of this review, immune responses induced by non-viral vectors have also been reported [19].”
BackgroundInfluentialHolmgaard, A. B., Askou, A. L., Jensen, E. G., Alsing, S., Bak, R. O., Mikkelsen, J. G., & Corydon, T. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.032 · Cited by 36 · cited 5×
“To explore this potential risk, guide RNAs with a 5′-triphosphate group (5′-ppp gRNAs) or gRNAs with 5′-hydroxyl were delivered to primary human CD4+ T cells with or without recombinant Cas9 as a ribonucleoprotein (RNP) complex.”
BackgroundInfluentialGene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 35 · cited 1×
“If applied early in the disease, it can take the form of gene correction, gene replacement or augmentation, which have a common goal in replacing the mutant gene with a healthy copy either at the chromosomal site in situ or by providing an additional healthy copy that is maintained extra-chromosomally [3].”
BackgroundRapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay
Guo, P., Zhang, J., Chrzanowski, M., Huang, J., Chew, H., Firrman, J. A., Sang, N., Diao, Y., & Xiao, W. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.007 · Cited by 33 · cited 1×
“AAVs are widely spread in the natural environment, and it has been reported that about 50–90% of the human population have been exposed to different AAV serotypes [27].”
BackgroundIkeda, Y., Goto, Y., Yonemitsu, Y., Miyazaki, M., Sakamoto, T., Ishibashi, T., Tabata, T., Ueda, Y., Hasegawa, M., Tobimatsu, S., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301973 · Cited by 30 · cited 1×
“However, mononuclear cell infiltration was found in the subretinal area in the high dose group, indicating that the dose is an essential parameter irrespective of the viral serotype [58].”
BackgroundGene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
Investigation of Cas9 Antibodies in the Human Eye
Toral, M. A., Charlesworth, C. T., Ng, B., Chemudupati, T., Homma, S., Nakauchi, H., Bassuk, A. G., Porteus, M. H., & Mahajan, V. B. (2022) · Nature Communications · doi:10.1038/s41467-022-28674-1 · Cited by 28 · cited 1×
“This study also showed that the antibodies’ levels were higher in serum than in vitreous liquid [26].”
BackgroundSafety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates
Weed, L., Ammar, M. J., Zhou, S., Wei, Z., Serrano, L. W., Sun, J., Lee, V., Maguire, A. M., Bennett, J., & Aleman, T. S. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.011 · Cited by 27 · cited 1×
“An increase in dose implies an increase in vector, transgene and promoter—each of which has independently and cumulatively shown to affect immune responses [30,52,86,87].”
BackgroundSustained Gene Expression in the Retina by Improved Episomal Vectors
Calado, S. M., Oliveira, A. V., Machado, S., Haase, R., & Silva, G. A. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0672 · Cited by 24 · cited 1×
“However, other aspects of inflammation were not observed, most likely because this study used an immunosuppressive regimen [70].”
BackgroundSemple-Rowland, S. L., & Berry, J. (2014) · Methods · doi:10.1016/j.ymeth.2013.06.026 · Cited by 23 · cited 2×
“While lentiviruses (LVs) can have a larger capacity that could reach up to 8 kb [11], they also integrate their genome to the target cells, which is a two-edged sword.”
BackgroundCRISPR Technology for Ocular Angiogenesis
Chung, S. H., Sin, T.-N., Ngo, T., & Yiu, G. C. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.594984 · Cited by 21 · cited 3×
“Two clinical trials have been conducted to test treatments for AMD [64] and retinoblastoma [65].”
BackgroundSemple‐Rowland, S. L., Coggin, W. E., Geesey, M., Eccles, K. S., Abraham, L. C., Pachigar, K., Ludlow, R., Khani, S. C., & Smith, W. C. (2010) · PubMed Central · Cited by 19
Evasion of Pre-Existing Immunity to Cas9: A Prerequisite for Successful Genome Editing In Vivo?
Wignakumar, T., & Fairchild, P. J. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-00237-2 · Cited by 19
Vendomèle, J., Dehmani, S., Khebizi, Q., Galy, A., & Fisson, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00504 · Cited by 18
Self-citationApplication of CRISPR-Cas9 in eye disease
Wu, W., Tang, L., D'Amore, P. A., & Lei, H. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.06.007 · Cited by 16 · cited 2×
“The presence of ocular barriers allows the eye to limit inflammation, and therefore, makes it a good target for CRISPR/Cas9-based gene therapies [33].”
BackgroundSubretinal Gene Delivery Using Helper-Dependent Adenoviral Vectors
Wu, L., Lam, S., Cao, H., Guan, R., Duan, R., van der Kooy, D., Bremner, R., Molday, R. S., & Hu, J. (2011) · Cell & Bioscience · doi:10.1186/2045-3701-1-15 · Cited by 13 · cited 1×
“A long-term gene expression without a decrease was reported [93].”
BackgroundCas9-Induced Immune Response: A Potential Caution for Human Genome Editing
Zhang, C. C. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.025 · Cited by 4 · cited 1×
“As an exogenous protein, Cas9 can be regarded as a foreign antigen in animals, and hence, can be presented by antigen-presenting cells (APC) to lymphocytes to induce host immune responses (Figure 1) [34].”
Background
Cited by
Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery
Qiu, C., Xia, F., Zhang, J., Shi, Q., Meng, Y., Wang, C., Pang, H., Gu, L., Xu, C., Guo, Q., et al. (2023) · Research · doi:10.34133/research.0148 · Cited by 224
“Owing to their natural endosomal escape property, viruses may act as potential vectors to deliver drugs; however, their high toxicity and immunogenicity hinder their application in clinical settings [132].”
BackgroundImmunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 165
“One example of these immune-privileged sites is the eye, where inflammatory responses are limited to avoid impact on vision (Benati et al., 2020; Ren et al., 2022).”
BackgroundGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Neumann, E. N., Bertozzi, T. M., Wu, E., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Coffey, A. A., Howard, M., Kamath, N., et al. (2024) · Science · doi:10.1126/science.ado7082 · Cited by 135
“Moreover, given that AAV genomes form concatenated epi-somes that chronically express the transgene, the bacterial enzyme Cas9 is likely to become antigenic over time ( 34 , 35 ); a large proportion of the human population already has an immune memory of it ( 36 ).”
Cheng, L., Zhu, Y., Ma, J., Aggarwal, A., Toh, W. H., Shin, C., Sangpachatanaruk, W., Weng, G. W., Kumar, R., & Mao, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c07615 · Cited by 80
Metadata
- Authors
- Ren, D., Fisson, S., Dalkara, D., & Ail, D.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Ail, Divya
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-09-19
- Volume
- 14
- Issue
- 9
- Pages
- 1973
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9502120
- OpenAlex
- W4296794285
- Semantic Scholar
- d4e1e7cffb88ed6e29f4da12069d83ddea75f0f0
- Cited by
- 52
- References
- 115
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 14 · 2023: 13
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- ERC Starting Grant (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Institut National de la Santé et de la Recherche Médicale (INSERM) (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Sorbonne Université (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- The Foundation Fighting Blindness (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Agence National de Recherche (ANR) RHU Light4Deaf (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- *LabEx LIFESENSES (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- *IHU FOReSIGHT (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- retinal gene therapy, CRISPR/Cas9 genome editing, immune response, viral vectors, non-viral vectors, inherited retinal disease, ocular inflammation, immune privilege, innate immunity, adaptive immunity, pre-existing immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.